NEW YORK, Feb. 25 - Peter Chambre, Celera's former chief operating officer, will become CEO of Cambridge Antibody Technology, CAT said on Monday. He is slated to start sometime in April.

"We are delighted that Peter has agreed to join CAT at this time when the company is positioning itself for transition to a profitable biopharmaceutical business," Peter Garland, CAT's chairman, said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.

Researchers report that while host genetics influence the oral microbiome, they don't appear to affect cavity-causing microbes, the Economist says.

Pandas' gut microbiomes change as what they eat changes with the seasons, writes Discover's Inkfish blog.

In PLOS this week: comparative genomic study of malaria-linked macaque parasite, search for apple root reference genes, and more.